PriceTargets.com logo

Viridian Therapeutics - VRDN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $35.80
  • Forecasted Upside: 46.48%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$24.44 As of 10/22/2024 01:00 AM ET
▼ -0.13 (-0.53%)

This chart shows the closing price for VRDN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Viridian Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRDN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRDN

Analyst Price Target is $35.80
▲ +46.48% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Viridian Therapeutics in the last 3 months. The average price target is $35.80, with a high forecast of $61.00 and a low forecast of $20.00. The average price target represents a 46.48% upside from the last price of $24.44.

This chart shows the closing price for VRDN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 polled investment analysts is to moderate buy stock in Viridian Therapeutics. This rating has held steady since April 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/26/2024BTIG ResearchBoost TargetBuy ➝ Buy$56.00 ➝ $61.00
9/19/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$44.00 ➝ $44.00
9/13/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$35.00 ➝ $44.00
9/12/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$25.00 ➝ $31.00
9/11/2024Needham & Company LLCBoost TargetBuy ➝ Buy$30.00 ➝ $38.00
9/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
9/10/2024BTIG ResearchBoost TargetBuy ➝ Buy$46.00 ➝ $56.00
8/30/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
8/28/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$35.00 ➝ $35.00
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
8/12/2024OppenheimerReiterated RatingOutperform ➝ Outperform$31.00 ➝ $28.00
7/29/2024WedbushReiterated RatingOutperform ➝ Outperform$42.00 ➝ $42.00
7/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
6/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
6/11/2024Wolfe ResearchInitiated CoverageOutperform$29.00
6/6/2024The Goldman Sachs GroupInitiated CoverageBuy$23.00
5/9/2024HC WainwrightLower TargetBuy ➝ Buy$37.00 ➝ $27.00
5/9/2024OppenheimerLower TargetOutperform ➝ Outperform$36.00 ➝ $31.00
5/9/2024LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
5/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$30.00
5/9/2024B. RileyDowngradeBuy ➝ Neutral$25.00 ➝ $20.00
3/21/2024B. RileyLower TargetBuy ➝ Buy$29.00 ➝ $25.00
3/20/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$30.00
2/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$37.00
2/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$30.00
2/28/2024WedbushBoost TargetOutperform ➝ Outperform$39.00 ➝ $40.00
12/19/2023OppenheimerBoost TargetOutperform ➝ Outperform$35.00 ➝ $36.00
12/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$37.00
12/14/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$35.00
12/4/2023WedbushReiterated RatingOutperform ➝ Outperform$37.00
11/14/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $38.00
11/14/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$35.00
10/31/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$44.00 ➝ $35.00
10/31/2023WedbushLower TargetOutperform ➝ Outperform$46.00 ➝ $37.00
10/30/2023Needham & Company LLCLower TargetBuy ➝ Buy$40.00 ➝ $30.00
9/13/2023Stifel NicolausReiterated RatingBuy ➝ Buy$40.00
9/13/2023WedbushReiterated RatingOutperform ➝ Outperform$46.00
8/10/2023Needham & Company LLCLower TargetBuy ➝ Buy$47.00 ➝ $40.00
8/10/2023HC WainwrightLower TargetBuy ➝ Buy$40.00 ➝ $37.00
8/9/2023OppenheimerLower TargetOutperform ➝ Outperform$40.00 ➝ $35.00
8/9/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$44.00
8/9/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$44.00 ➝ $42.00
8/9/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$46.00 ➝ $39.00
7/11/2023WedbushLower Target$48.00 ➝ $45.00
6/14/2023BTIG ResearchInitiated CoverageBuy$46.00
5/30/2023Royal Bank of CanadaInitiated CoverageOutperform$44.00
5/10/2023OppenheimerLower Target$45.00 ➝ $40.00
5/10/2023JMP SecuritiesLower Target$46.00 ➝ $44.00
4/17/2023Wells Fargo & CompanyInitiated CoverageOverweight$46.00
4/10/2023Needham & Company LLCReiterated RatingBuy$47.00
3/29/2023Stifel NicolausInitiated CoverageBuy$49.00
3/9/2023LADENBURG THALM/SH SHReiterated RatingBuy$40.00
3/9/2023HC WainwrightBoost TargetBuy$35.00 ➝ $40.00
2/7/2023HC WainwrightReiterated RatingBuy$35.00
1/10/2023B. RileyBoost Target$40.00 ➝ $46.00
1/9/2023Leerink PartnersBoost TargetOutperform$40.00 ➝ $45.00
12/19/2022CowenInitiated CoverageOutperform$45.00
12/19/2022Needham & Company LLCInitiated CoverageBuy$45.00
12/19/2022CowenInitiated CoverageOutperform
12/16/2022Credit Suisse GroupInitiated CoverageOutperform$51.00
12/1/2022HC WainwrightInitiated CoverageBuy$35.00
11/17/2022WedbushBoost Target$43.00
11/15/2022JMP SecuritiesLower TargetMarket Outperform$47.00 ➝ $46.00
8/16/2022B. RileyBoost Target$25.00 ➝ $40.00
8/16/2022LADENBURG THALM/SH SHBoost TargetBuy$33.00 ➝ $40.00
8/15/2022Evercore ISIBoost Target$40.00 ➝ $50.00
8/15/2022Leerink PartnersBoost TargetOutperform$32.00 ➝ $40.00
6/23/2022B. RileyInitiated CoverageBuy$25.00
3/11/2022JMP SecuritiesLower TargetMarket Outperform$36.00 ➝ $31.00
12/21/2021LADENBURG THALM/SH SHReiterated RatingBuy$36.00
11/18/2021Leerink PartnersInitiated CoverageOutperform$32.00
11/5/2021JMP SecuritiesLower TargetPositive ➝ Outperform$44.00 ➝ $36.00
10/12/2021Evercore ISIInitiated CoverageOutperform$40.00
8/24/2021Lifesci CapitalReiterated RatingOutperform
1/25/2021LADENBURG THALM/SH SHInitiated CoverageBuy$40.00
1/20/2021Jefferies Financial GroupBoost TargetBuy$18.00 ➝ $28.00
(Data available from 10/23/2019 forward)

News Sentiment Rating

1.00 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
3/26/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 7 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 9 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 10 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 16 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 12 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024

Current Sentiment

  • 12 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Viridian Therapeutics logo
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $24.44
Low: $23.93
High: $24.69

50 Day Range

MA: $19.52
Low: $13.47
High: $24.98

52 Week Range

Now: $24.44
Low: $10.93
High: $25.39

Volume

410,107 shs

Average Volume

1,118,976 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Viridian Therapeutics?

The following equities research analysts have issued research reports on Viridian Therapeutics in the last year: B. Riley, BTIG Research, HC Wainwright, JMP Securities, LADENBURG THALM/SH SH, Needham & Company LLC, Oppenheimer Holdings Inc., Royal Bank of Canada, The Goldman Sachs Group, Inc., Wedbush, and Wolfe Research.
View the latest analyst ratings for VRDN.

What is the current price target for Viridian Therapeutics?

10 Wall Street analysts have set twelve-month price targets for Viridian Therapeutics in the last year. Their average twelve-month price target is $35.80, suggesting a possible upside of 46.5%. BTIG Research has the highest price target set, predicting VRDN will reach $61.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $20.00 for Viridian Therapeutics in the next year.
View the latest price targets for VRDN.

What is the current consensus analyst rating for Viridian Therapeutics?

Viridian Therapeutics currently has 2 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for VRDN.

What other companies compete with Viridian Therapeutics?

Other companies that are similar to Viridian Therapeutics include Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Psychemedics, Option Care Health and Hims & Hers Health. Learn More about companies similar to Viridian Therapeutics.

How do I contact Viridian Therapeutics' investor relations team?

Viridian Therapeutics' physical mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The company's listed phone number is (617) 272-4600 and its investor relations email address is [email protected]. The official website for Viridian Therapeutics is www.viridiantherapeutics.com. Learn More about contacing Viridian Therapeutics investor relations.